Literature DB >> 19028871

Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis.

Francisco J Quintana1, Mauricio F Farez, Vissia Viglietta, Antonio H Iglesias, Yifat Merbl, Guillermo Izquierdo, Miguel Lucas, Alexandre S Basso, Samia J Khoury, Claudia F Lucchinetti, Irun R Cohen, Howard L Weiner.   

Abstract

Multiple sclerosis (MS) is a chronic relapsing disease of the central nervous system (CNS) in which immune processes are believed to play a major role. To date, there is no reliable method by which to characterize the immune processes and their changes associated with different forms of MS and disease progression. We performed antigen microarray analysis to characterize patterns of antibody reactivity in MS serum against a panel of CNS protein and lipid autoantigens and heat shock proteins. Informatic analysis consisted of a training set that was validated on a blinded test set. The results were further validated on an independent cohort of relapsing-remitting (RRMS) samples. We found unique autoantibody patterns that distinguished RRMS, secondary progressive (SPMS), and primary progressive (PPMS) MS from both healthy controls and other neurologic or autoimmune driven diseases including Alzheimer's disease, adrenoleukodystropy, and lupus erythematosus. RRMS was characterized by autoantibodies to heat shock proteins that were not observed in PPMS or SPMS. In addition, RRMS, SPMS, and PPMS were characterized by unique patterns of reactivity to CNS antigens. Furthermore, we examined sera from patients with different immunopathologic patterns of MS as determined by brain biopsy, and we identified unique antibody patterns to lipids and CNS-derived peptides that were linked to each type of pathology. The demonstration of unique serum immune signatures linked to different stages and pathologic processes in MS provides an avenue to monitor MS and to characterize immunopathogenic mechanisms and therapeutic targets in the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028871      PMCID: PMC2596207          DOI: 10.1073/pnas.0806310105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

Review 1.  Systemic lupus erythematosus.

Authors:  David P D'Cruz; Munther A Khamashta; Graham R V Hughes
Journal:  Lancet       Date:  2007-02-17       Impact factor: 79.321

Review 2.  Real and artificial immune systems: computing the state of the body.

Authors:  Irun R Cohen
Journal:  Nat Rev Immunol       Date:  2007-07       Impact factor: 53.106

3.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

Review 4.  Pathogenetic role of autoantibodies in neurological diseases.

Authors:  J J Archelos; H P Hartung
Journal:  Trends Neurosci       Date:  2000-07       Impact factor: 13.837

5.  Effects of 5-aminoisoquinolinone, a water-soluble, potent inhibitor of the activity of poly (ADP-ribose) polymerase on the organ injury and dysfunction caused by haemorrhagic shock.

Authors:  M C McDonald; H Mota-Filipe; J A Wright; M Abdelrahman; M D Threadgill; A S Thompson; C Thiemermann
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

6.  Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.

Authors:  Kevin C O'Connor; Katherine A McLaughlin; Philip L De Jager; Tanuja Chitnis; Estelle Bettelli; Chenqi Xu; William H Robinson; Sunil V Cherry; Amit Bar-Or; Brenda Banwell; Hikoaki Fukaura; Toshiyuki Fukazawa; Silvia Tenembaum; Susan J Wong; Norma P Tavakoli; Zhannat Idrissova; Vissia Viglietta; Kevin Rostasy; Daniela Pohl; Russell C Dale; Mark Freedman; Lawrence Steinman; Guy J Buckle; Vijay K Kuchroo; David A Hafler; Kai W Wucherpfennig
Journal:  Nat Med       Date:  2007-01-12       Impact factor: 53.440

Review 7.  Multiple sclerosis: a complicated picture of autoimmunity.

Authors:  Henry F McFarland; Roland Martin
Journal:  Nat Immunol       Date:  2007-09       Impact factor: 25.606

8.  Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor.

Authors:  Francisco J Quintana; Alexandre S Basso; Antonio H Iglesias; Thomas Korn; Mauricio F Farez; Estelle Bettelli; Mario Caccamo; Mohamed Oukka; Howard L Weiner
Journal:  Nature       Date:  2008-03-23       Impact factor: 49.962

9.  Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination.

Authors:  Shalina S Ousman; Beren H Tomooka; Johannes M van Noort; Eric F Wawrousek; Kevin C O'Connor; David A Hafler; Raymond A Sobel; William H Robinson; Lawrence Steinman
Journal:  Nature       Date:  2007-06-13       Impact factor: 49.962

Review 10.  Primary-progressive multiple sclerosis.

Authors:  David H Miller; Siobhan M Leary
Journal:  Lancet Neurol       Date:  2007-10       Impact factor: 44.182

View more
  101 in total

1.  Antigen microarrays identify CNS-produced autoantibodies in RRMS.

Authors:  F J Quintana; M F Farez; G Izquierdo; M Lucas; I R Cohen; H L Weiner
Journal:  Neurology       Date:  2012-01-18       Impact factor: 9.910

Review 2.  The innate immune system in demyelinating disease.

Authors:  Lior Mayo; Francisco J Quintana; Howard L Weiner
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 3.  New tools for classification and monitoring of autoimmune diseases.

Authors:  Holden T Maecker; Tamsin M Lindstrom; William H Robinson; Paul J Utz; Matthew Hale; Scott D Boyd; Shai S Shen-Orr; C Garrison Fathman
Journal:  Nat Rev Rheumatol       Date:  2012-05-31       Impact factor: 20.543

4.  Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays.

Authors:  Chao-Jun Hu; Guang Song; Wei Huang; Guo-Zhen Liu; Chui-Wen Deng; Hai-Pan Zeng; Li Wang; Feng-Chun Zhang; Xuan Zhang; Jun Seop Jeong; Seth Blackshaw; Li-Zhi Jiang; Heng Zhu; Lin Wu; Yong-Zhe Li
Journal:  Mol Cell Proteomics       Date:  2012-05-30       Impact factor: 5.911

5.  IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39.

Authors:  Ivan D Mascanfroni; Ada Yeste; Silvio M Vieira; Evan J Burns; Bonny Patel; Ido Sloma; Yan Wu; Lior Mayo; Rotem Ben-Hamo; Sol Efroni; Vijay K Kuchroo; Simon C Robson; Francisco J Quintana
Journal:  Nat Immunol       Date:  2013-09-01       Impact factor: 25.606

6.  Anoctamin 2 identified as an autoimmune target in multiple sclerosis.

Authors:  Burcu Ayoglu; Nicholas Mitsios; Ingrid Kockum; Mohsen Khademi; Arash Zandian; Ronald Sjöberg; Björn Forsström; Johan Bredenberg; Izaura Lima Bomfim; Erik Holmgren; Hans Grönlund; André Ortlieb Guerreiro-Cacais; Nada Abdelmagid; Mathias Uhlén; Tim Waterboer; Lars Alfredsson; Jan Mulder; Jochen M Schwenk; Tomas Olsson; Peter Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-09       Impact factor: 11.205

7.  Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.

Authors:  Marie Cathrin Mayer; Edgar Meinl
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

8.  Pathologic heterogeneity persists in early active multiple sclerosis lesions.

Authors:  Imke Metz; Stephen D Weigand; Bogdan F G Popescu; Josa M Frischer; Joseph E Parisi; Yong Guo; Hans Lassmann; Wolfgang Brück; Claudia F Lucchinetti
Journal:  Ann Neurol       Date:  2014-05-13       Impact factor: 10.422

9.  Tumor-associated and disease-associated autoantibody repertoires in healthy colostrum and maternal and newborn cord sera.

Authors:  Asaf Madi; Sharron Bransburg-Zabary; Ayala Maayan-Metzger; Gittit Dar; Eshel Ben-Jacob; Irun R Cohen
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

Review 10.  The pathological spectrum of CNS inflammatory demyelinating diseases.

Authors:  Wei Hu; Claudia F Lucchinetti
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.